Nektar Therapeutics Common Stock (NKTR)

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

63

Website

www.nektar.com/

Fundamentals

1-day range

$71.2$74.65

Market cap

$2.48B

P/E (trailing)

—

P/E (forward)

-6.69

EPS (trailing)

$-8.32

Dividend yield

—

Beta

1.23

Avg. volume

914.5K

Forecasts

10 analyst ratings

Nektar Therapeutics Common Stock Competitors

Chosen by industry and closest market cap.

• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.48BP/E —
  $27.87$109
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.47BP/E —
  $2.99$7.72
• KLRA

  Kailera Therapeutics Inc. Common Stock

  $16.26

  ▼ 12.25%
  Market cap $2.44BP/E —
  $16.19$28.23
• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.54BP/E —
  $18.29$39.89
• NRIX

  Nurix Therapeutics Inc. Common stock

  $26.19

  ▼ 2.57%
  Market cap $2.62BP/E —
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.63BP/E —
  $6.93$20.22
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $2.32BP/E —
  $13.18$34.29

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis
  benzinga · 8/25/2026
• JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
  Benzinga · 8/21/2026
• Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
  SeekingAlpha · 8/14/2026
• Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
  Benzinga · 8/13/2026

• Jonathan Zalevsky · July 24, 2026 · Grant

  16.5K
• Howard W. Robin · July 24, 2026 · Grant

  57.2K
• Jonathan Zalevsky · June 30, 2026 · Sale

  5.7K @ $70
• Howard W. Robin · June 17, 2026 · Sale

  4.5K @ $61.65
• Howard W. Robin · June 17, 2026 · Sale

  5.5K @ $60.81
• Howard W. Robin · June 16, 2026 · Sale

  4.7K @ $60.71
• Howard W. Robin · June 16, 2026 · Sale

  5.3K @ $59.97
• Jonathan Zalevsky · May 19, 2026 · Sale

  199 @ $65.51
• Howard W. Robin · May 19, 2026 · Sale

  444 @ $65.51

Institutional Ownership

March 31, 2026

Total shares held

27.57M

Total value held

$1.94B

Institutional holders

200